Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Coronavirus disease 2019 (COVID-19) is a disease caused by a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). The most characteristic symptom of patients with COVID-19 is respiratory distress, leading to inability to sustain spontaneous breathing. In addition, patients with COVID-19 have dyspnea and respiratory muscle fatigue. Therefore, it is necessary to use strategies that minimize the impact of COVID-19 on the respiratory muscles, accelerating the ventilatory weaning process and optimizing the functional capacity of the involved muscles. Over the past years, evidence has shown the effectivity of photobiomodulation therapy (PBMT) combined with static magnetic field (sMF) (PBMT/sMF) in delaying muscle fatigue, decrease in markers of inflammatory damage and oxidative stress of skeletal muscle. These effects result in an improvement in the functional capacity of the irradiated muscles by PBMT/sMF. However, do date, there is a lack of evidence regarding the effects of PBMT/sMF on the respiratory muscles. Therefore, the irradiation of PBMT/sMF may result in improvement in the functional capacity of respiratory muscles in patients with COVID-19, accelerating the ventilatory weaning process of the patients intubated due to respiratory failure. In addition, the irradiation of PBMT/sMF may induce the increase of anti-inflammatory mediators' activity in patients with COVID-19. Thus, the aim of this project is to investigate the effects of PBMT/sMF on respiratory muscles of patients admitted to the Intensive Care Unit (ICU) with COVID-19 using invasive mechanical ventilation.
Description: Number of days hospitalized in the ICU until discharge or death.
Measure: Time until discharge Time: From date of randomization until the date of discharge or date of death from any cause, whichever came first, assessed up to 20 days.Description: Rate of how many people survived and were discharged and how many died.
Measure: Survival rate Time: From date of randomization until the date of discharge or date of death from any cause, whichever came first, assessed up to 20 days.Description: Diaphragm thickness will be measured by ultrasound.
Measure: Diaphragm muscle function Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Description: Platelet count will be measured by blood test.
Measure: Platelet count Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Description: Leukogram will be measured by blood test.
Measure: Leukogram Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Description: Erythrogram will be measured by blood test.
Measure: Erythrogram Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Description: C-reactive protein will be measured by blood test.
Measure: C-reactive protein Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Description: D-dimer will be measured by blood test.
Measure: D-dimer Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Description: Immunoglobulin G will be measured by blood test.
Measure: Immunoglobulin G Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Description: Immunoglobulin M will be measured by blood test.
Measure: Immunoglobulin M Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Description: The levels of PEEP will be measured using a mechanical ventilator.
Measure: Levels of positive end-expiratory pressure (PEEP) Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Description: The levels of FiO2 will be measured using a mechanical ventilator.
Measure: Fraction of inspired oxygen (FiO2) Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Description: PO2 will be measured by arterial blood gas analysis.
Measure: Arterial partial pressure of oxygen (PO2) Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Description: PO2/FiO2 ratio will be measured by arterial blood gas analysis.
Measure: Arterial partial pressure of oxygen (PO2)/Fraction of inspired oxygen (FiO2) ratio Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Description: Levels of TNF-α will be measured by blood test.
Measure: Levels of tumor necrosis factor-α (TNF-α) Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Description: Levels of vitamin D will be measured by blood test.
Measure: Levels of vitamin D Time: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports